Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03136653
Other study ID # MP0250-CP201
Secondary ID 2016-002771-10
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date May 23, 2017
Est. completion date January 13, 2021

Study information

Verified date August 2021
Source Molecular Partners AG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy, safety, tolerability, pharmacokinetics (PK), immunogenicity and efficacy of MP0250 in combination with bortezomib + dexamethasone in patients with refractory and relapsed multiple myeloma (RRMM). MP0250 is a multi-DARPin® drug candidate with three specificities, able to simultaneously neutralize the activities of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) and also to bind to human serum albumin (HSA) to give an increased plasma half-life and potentially enhanced tumor penetration.


Recruitment information / eligibility

Status Completed
Enrollment 33
Est. completion date January 13, 2021
Est. primary completion date October 12, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients with MM who have received: - Part 1 =2 lines of therapy (including bortezomib and an IMiD) and have shown no response (i.e. stable disease) to, have progressed on the most recent treatment or have progressed within 60 days of the most recent therapy - Part 2 =2 lines of prior therapy that included a proteasome inhibitor (bortezomib, carfilzomib or both) and an IMiD (thalidomide, lenalidomide and/or pomalidomide) either alone or in combination and a response no better than SD lasting at least 4 months on a bortezomib- or carfilzomib-based regimen as last line of therapy or progression on treatment or within 60 days of stopping a bortezomib- or carfilzomib-based regimen as last line of therapy. Note: For transplant-eligible patients enrolled to Part 1 or Part 2, induction plus conditioning chemotherapy/ASCT +/- maintenance therapy constitute one regimen. 2. Presence of a measurable disease with at least one of the following criteria: - Serum M protein =0.5 g/dL, or - Urine M protein =200 mg/24 h, or - Involved serum free light chain (FLC) levels >100 mg/L and abnormal kappa/lambda (?/?) ratio in patients without detectable serum or urine M protein, or - For patients with immunoglobulin A (IgA) myeloma whose disease can only be reliably measured by quantitative immunoglobulin measurement, a serum IgA level =0.5g/dL. 3. Eastern Cooperative Oncology Group (ECOG) performance status (0 to 1) 4. Life expectancy >3 months 5. Adequate hepatic function at Screening, with aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <3x ULN and total bilirubin <2 x upper limit of normal (ULN). For patients with Gilbert's syndrome (Gilbert-Meulengracht syndrome), higher bilirubin of 5 x ULN is acceptable 6. Absolute neutrophil count (ANC) =1000/mm3 at Screening. Screening ANC must be independent of growth factor support for =1 week 7. Hemoglobin =8.0 g/dL at Screening. Use of erythropoietic stimulating factors and red blood cell (RBC) transfusions per institutional guidelines is allowed, however most recent RBC transfusion must not have been done within 7 days prior to obtaining screening hemoglobin 8. Platelet count =50 000/mm3 at Screening. Patients must not have received platelet transfusions for at least 1 week prior to obtaining the screening platelet count 9. Calculated or measured creatinine clearance (CrCl) of = 45 mL/min at Screening based on the Cockcroft and Gault formula 10. Serum albumin concentration = 25 g/L. Note: Patients with lower levels of serum albumin at baseline may receive albumin supplementation to comply with this criterion 11. Males and females =18 years of age 12. Male Participants: A male participant must agree to use a highly effective contraception 13. Female Participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: 1. Not a woman of childbearing potential (WOCBP) OR 2. A WOCBP who agrees to follow contraceptive guidance from the Screening visit, during the treatment period and for at least 3 months after the last dose of study treatment 14. Capable of giving signed informed consent Exclusion Criteria: 1. Patients with the following diseases: - Monoclonal gammopathy of undetermined significance (MGUS) of non- immunoglobulin (Ig)M and IgM subtypes, - Light chain MGUS, - Solitary plasmacytoma (alone or with minimal marrow involvement), - Systemic Ig light chain amyloidosis, - Waldenstrom's Macroglobulinemia, - Myelodysplastic syndrome, - Plasma cell leukemia defined as a plasma cell count >2000/mm3 - Polyneuropathy, organomegaly endocrinopathy, monoclonal protein, and skin changes (POEMS) syndrome 2. Peripheral neuropathy Grade 2 or higher at Screening or patients with a history of Grade 3/4 neuropathy or Grade 2 with pain 3. Prior or concurrent malignancy, except for: Adequately treated basal cell or squamous cell skin cancer, carcinoma in-situ of the cervix or breast or very low and low risk prostate cancer in active surveillance or any other cancer from which the patient has been disease-free for >5 years 4. Active congestive heart failure (New York Heart Association [NYHA] Class III to IV), symptomatic cardiac ischemia, or conduction abnormalities uncontrolled by conventional intervention. Myocardial infarction within 6 months prior to screening 5. Uncontrolled hypertension (defined as systolic blood pressure (SBP) >150 mm Hg diastolic blood pressure (DBP) >100 mm Hg despite antihypertensive medication) 6. Stroke, or transient ischemic attack within 6 months of Screening, clinically significant bleeding and vascular disease 7. Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months 8. Significant concurrent, uncontrolled medical condition including, but not limited to, severe wound healing complication, renal (except related to MM), hepatic, hematological except MM, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease 9. Acute active infection requiring systemic antibiotics, antiviral (except antiviral therapy directed at hepatitis B) or antifungal agents within 14 days prior to screening 10. Clinical signs of or documented leptomeningeal or cerebral involvement of MM 11. Treatment with ixazomib as last line of therapy in Part 2 12. Therapy with approved or investigational anticancer therapeutics within 21 days (or in the case of nitrosureas, within 6 weeks) prior to treatment (except anti-myeloma treatment with a carfilzomib- or bortezomib-based regimen in Part 2) Note: Patients must have recovered from pre-existing, treatment-related adverse events to Grade 1 or lower 13. Autologous stem cell transplantation (ASCT) within 12 weeks before the date of enrollment 14. Prior allogeneic stem cell transplantation with active graft-versus-host-disease 15. Major surgery within 21 days prior to Screening 16. Immunotherapy within 21 days prior to Screening 17. Newly initiated therapy with bisphosphonate or RANKL (within two months prior to Screening). Patients on stable regimen with bisphosphonate or receptor activator of nuclear kappa-B ligand (RANKL)-inhibitor therapy over 2 months can continue these treatments at the same dose. No new therapy with bisphosphonate/RANKL inhibitor is allowed during the study 18. Radiation therapy within 2 months of Cycle 1, Day 1 is not permitted Except for local low-dose, palliative radiation to bone lesions for pain control. 19. Patients who have received treatment with any non-marketed product within 21 days prior to treatment start 20. Current participation in any other interventional clinical study 21. Patients known or suspected of not being able to comply with a study protocol (e.g. due to alcoholism, drug dependency or psychological disorder) 22. Known infection with human immunodeficiency virus or serologic status reflecting active hepatitis B or hepatitis C virus infection as follows: - Not receiving or not responding to anti-viral therapy. - HCV RNA detected 23. Patients with contraindication to dexamethasone or bortezomib according to the applicable local product label 24. Known hypersensitivity to components of the investigational product, for example, histidine buffer or the Tween diluent

Study Design


Intervention

Biological:
MP0250 plus BOR+DEX
6 mg/kg or 8 mg/kg or 12 mg/kg of MP0250, IV (in the vein,) on day 1 of each 21 day cycle. Bortezomib and Dexamethasone according to label. Number of Cycles: until progression or unacceptable toxicity develops.

Locations

Country Name City State
Austria Landeskliniken Salzburg Saint Johanns-Spital Salzburg
Austria Hanusch Krankenhaus Wiener Gebietskrankenkasse Wien Vienna
Czechia Fakultní Nemocnice Brno Brno Jihormoravsky Krav
Czechia Fakultní Nemocnice Ostrava Ostrava - Poruba Severomoravsky KRAJ
Denmark Odense University Hospital Odense C
Denmark Vejle Sygehus Vejle
Germany Universitätsklinikum Dresden Dresden Sachsen
Germany Universitaetsklinikum Essen Essen
Germany Asklepios Klinik Altona Hamburg-Altona Hamburg
Germany Universitätsklinikum Heidelberg Heidelberg
Germany Universitätsklinikum Leipzig Leipzig
Germany Universitätsklinikum Münster Münster
Germany Universitätsklinikum Würzburg Würzburg
Italy Azienda Ospedaliera Policlinico di Bari Bari
Italy Azienda Ospedaliero Universitaria di Bologna Policlinico Sant'Orsola-Malpighi Bologna
Italy Arcispedale Santa Maria Nuova Reggio Emilia
Italy Fondazione Policlinico Universitario Agostino Gemelli Roma
Italy Azienda Ospedaliera Città della Salute e della Scienza di Torino Torino
Poland Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespól Szpitali Miejskich Chorzów Slaskie
Poland Uniwersyteckie Centrum Kliniczne Gdansk
Poland Szpital Uniwersytecki w Krakowie Kraków
Poland Centrum Onkologii Ziemi Lubelskiej Lublin
Poland Szpital Wojewódzki w Opolu Opole
Poland Instytut Hematologii i Transfuzjologii Warszawa

Sponsors (1)

Lead Sponsor Collaborator
Molecular Partners AG

Countries where clinical trial is conducted

Austria,  Czechia,  Denmark,  Germany,  Italy,  Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Part 1: Overall Response Rate (ORR) Defined as the number of participants achieving a complete response (CR), very good partial response (VGPR), or partial response (PR) during treatment with MP0250 plus bortezomib+dexamethasone determined by the Investigator in part 1. 24 months
Primary Part 2: ORR Defined as the number of participants achieving a confirmed, stringent complete response (sCR), very good partial response (VGPR), or partial response (PR) during treatment with MP0250 plus bortezomib+dexamethasone determined by the Investigator in part 2. 24 months
Secondary Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events 24 months
Secondary Number of Participants who Experienced One or More Treatment-Emergent SAEs 24 months
Secondary Number of Participants Who Experienced One or More Common Terminology Criteria for Adverse Events (CTCAE) Grade = 3 Adverse Events 24 months
Secondary Number of Participants with a Clinical Significant Change from Baseline in Laboratory Results 24 months
Secondary Number of Participants with a Clinically Significant Change from Baseline in Vital Signs 24 months
Secondary Number of Participants with a Clinically Significant Change from Baseline in Electrocardiogram (ECG) Results 24 months
Secondary Number of Participants with a Positive Anti-drug Antibody (ADA) Result 24 months
Secondary Titer of Anti-drug Antibodies (ADA) 24 months
Secondary Time Course of Anti-drug Antibodies 24 months
Secondary Duration of Response (DOR) DOR is defined as the duration from first observation of partial response (PR) or better until disease progression, or death from myeloma. 24 months
Secondary Progression Free Survival (PFS) PFS is determined as the time from first study treatment until progression or death from myeloma. 24 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01435720 - Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) Phase 1/Phase 2
Recruiting NCT04094961 - Ixazomib + Pomalidomide + Dexamethasone In MM Phase 1/Phase 2
Recruiting NCT06068400 - Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Multiple Myeloma N/A
Recruiting NCT03601624 - Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans Phase 2
Recruiting NCT05020444 - TriPRIL CAR T Cells in Multiple Myeloma Phase 1
Not yet recruiting NCT03706547 - Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM Phase 1
Active, not recruiting NCT02970747 - Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients
Not yet recruiting NCT06411301 - A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors Phase 1
Completed NCT01965353 - A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma Phase 1
Not yet recruiting NCT05581875 - A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory Phase 1/Phase 2
Terminated NCT03687125 - Tinostamustine Conditioning and Autologous Stem Cell Phase 1/Phase 2
Recruiting NCT06282978 - Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes Phase 2
Recruiting NCT06158412 - All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma Phase 2
Active, not recruiting NCT03030261 - Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma Phase 2
Recruiting NCT04925193 - Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma Phase 2
Recruiting NCT05121103 - A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma Phase 1
Recruiting NCT04603872 - CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies Early Phase 1
Recruiting NCT04657861 - APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma Early Phase 1
Terminated NCT05191472 - Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies Phase 2
Recruiting NCT04162353 - BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma Phase 1